Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRMakoto Maemondo, Toshihiro Nukiwa, Shoji Okinaga et al.|New England Journal of Medicine|2010Cited by 5.6k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Makoto Maemondo, Tatsuro Fukuhara et al.|The Lancet Oncology|2019Cited by 636
First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for ChemotherapyAkira Inoue, Koichi Hagiwara, Kunihiko Kobayashi et al.|Journal of Clinical Oncology|2009Cited by 516
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 StudyYukio Hosomi, Satoshi Morita, Shunichi Sugawara et al.|Journal of Clinical Oncology|2019Cited by 483
Mutations in the <i>SLC34A2</i> Gene are Associated with Pulmonary Alveolar MicrolithiasisHuqun, Koichi Hagiwara, Shinyu Izumi et al.|American Journal of Respiratory and Critical Care Medicine|2006Cited by 196